Affiliation:
1. V.I. Vernadsky Crimean Federal University
Abstract
The issues of primary and secondary prevention of cardiovascular diseases are given great attention, since they still occupy a leading place in the structure of morbidity and mortality in the general population. Numerous randomized clinical studies have proven the crucial role of dyslipidemia in the occurrence and progression of atherosclerosis, the main risk factor for associated cardiovascular diseases. The analysis and discussion of modern methods of pharmacological treatment of dyslipidemias from the standpoint of the recommendations of the European Society of Cardiology and the European Society of Atherosclerosis 2019. The characteristics of lipid- lowering drug groups and their place in the treatment of dyslipidemia are given. A new class of hypolipidemic drugs – PCSK9 inhibitors with high efficacy and safety according to multicenter double-blind randomized clinical trials is presented.
Subject
Process Chemistry and Technology,Economic Geology,Fuel Technology
Reference21 articles.
1. Mach F., Baigent C., Catapano A. L., Koskinas K. C., Casula M., Badimon L. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modi㈷cation to reduce cardiovascular risk. Eur Heart J 2019;40(37):27-38. doi: 10.1093/eurheartj/ehz455., Mach F., Baigent C., Catapano A. L., Koskinas K. C., Casula M., Badimon L. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modi㈷cation to reduce cardiovascular risk. Eur Heart J 2019;40(37):27-38. doi: 10.1093/eurheartj/ehz455.
2. Catapano A. L., Graham L., DeBacker G., Wiklund O., Chapman M. J. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016;37(39):2999-3058., Catapano A. L., Graham L., DeBacker G., Wiklund O., Chapman M. J. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016;37(39):2999-3058.
3. Бубнова М. Г. Лечение атерогенных дислипидемий: современные принципы и новые возможности. CardioСоматика. 2017;8(2):51-58., Bubnova M. G. Lechenie aterogennyh dislipidemiy: sovremennye principy i novye vozmozhnosti. CardioSomatika. 2017;8(2):51-58.
4. Березин А. Е. Глобальная васкулярная протекция у пациентов с артериальной гипертензией и гиперлипидемией. Украинский медицинский часопис. 2013;4(96):53-58., Berezin A. E. Global'naya vaskulyarnaya protekciya u pacientov s arterial'noy gipertenziey i giperlipidemiey. Ukrainskiy medicinskiy chasopis. 2013;4(96):53-58.
5. Карпов Ю. А. Эволокумаб и регрессия атеросклеротического поражения по данным внутрисосудистого ультразвукового исследования коронарных артерий. Атмосфера. Новости кардиологии. 2017;2:2-8., Karpov Yu. A. Evolokumab i regressiya ateroskleroticheskogo porazheniya po dannym vnutrisosudistogo ul'trazvukovogo issledovaniya koronarnyh arteriy. Atmosfera. Novosti kardiologii. 2017;2:2-8.